Abstract

Diabetic obesity, the coexistence of obesity with type 2 diabetes mellitus (T2DM), represents a syndemic 
condition characterized by chronic hyperglycemia, insulin resistance, low-grade inflammation, and profound 
pharmacokinetic variability. Conventional antidiabetic regimens, including multiple daily insulin injections and 
oral agents, are often insufficient to maintain tight glycemic control in these patients without increasing the risk 
of hypoglycemia and weight gain. Glucose-responsive nanomaterials (GRNs) have emerged as a promising 
strategy to achieve adaptive, self-regulated drug delivery that couples therapeutic release directly to fluctuating 
blood glucose levels. By integrating molecular glucose sensors with nanoscale carriers, these systems can 
theoretically sense hyperglycemia, trigger drug release, and attenuate delivery as euglycemia is restored. This 
review discusses the pathophysiological context of diabetic obesity that motivates GRN design, outlines key 
engineering principles, and summarizes major classes of glucose-responsive mechanisms, including glucose 
oxidase-based, phenylboronic acid-based, and glucose-binding protein platforms. We further highlight 
representative nano-architectures, such as polymeric nanoparticles, liposomes, micelles, hydrogels, and 
microneedle patches, and consider how they can be tailored for obese patients with altered tissue perfusion and 
drug distribution. Preclinical studies in obese and diabetic animal models demonstrate promising glucose
regulated insulin release and weight-modulating co-therapies, though clinical translation remains nascent. 
Finally, we discuss challenges related to biocompatibility, long-term stability, manufacturability, regulatory 
approval, and equity of access, and outline future directions, including multi-analyte responsive systems, closed
loop integration with digital health, and personalized nanomedicine for diabetic obesity.